Olaf Cremer (1971) was trained as an anesthesiologist, intensivist and clinical epidemiologist. He has worked as a consultant in the department of intensive care medicine of the UMCU since 2007. Dr. Cremer has designed and co-developed the patient data management system that is currently in use. His detailed knowledge of the system and computer programming skills allow him to explore this clinical database as a rich source of information for several research projects within the division.
Prof. Cremer obtained his PhD degree in 2005 with a doctoral thesis on goal-directed management of patients with severe traumatic brain injury. His thesis included both experimental clinical studies focused on cerebrovascular pathophysiology, as well as large cohort studies focused on patient outcomes. Since 2010 he has been studying the clinical epidemiology of infections in the ICU and/or the postoperative setting. He is one of the PI's of the MARS consortium, a multicentre collaboration aimed at developing new molecular technologies for early diagnosis and risk stratification of sepsis. More recently he initiated the PLUTO project, a longitudinal biorepository of patients undergoing elective surgery in the UMCU. The main focus areas of his research group include:

1 - diagnostic uncertainty in early detection of sepsis

2 - attributable morbidity and mortality of (nosocomial) sepsis and acute inflammation

3 - decision support for diagnosis and treatment of sepsis

Cremer has been mentoring 18 PhD students to date.

Committees and advisory boards

2023 - Chair of the Science & Innovation Committee, Dutch Society of Intensive Care (NVIC)

2023 - ISAB member for the International Clinical Research Center (ICRC), St. Anne's Univeristy Hospital, Brno, Czech Republic

2023 - Advisory board member for Research and Innovation, Dutch Association of Medical Specialists (FMS) 

2021 - GlaxoSmithKline (otilimab drug development) - money paid to UMCU

2021 - Parexel (adrenomed ENCOURAGE program) - money paid to UMCU

Industry collaborations

2015-2019 - ImmuneXpress Inc. (Seattle, WA) – Unrestricted research grant (105K)

2021-2022 - Abionic SA (Epalinges, Switzerland) – Unrestricted research grant (60K)

2022-2024 - Prolira BV (Utrecht, Netherlands) - In kind contributions to research (50K)

2023-2026 - Presymptom Health Ltd. (Porton Down, UK) - In kind and in cash contributions to research

Speaker fees

2022 - Committee for European Education in Anaesthesiology

Memberships

ESICM

NVIC